Request Legal Help Now - Free
LAWSUITS NEWS & LEGAL INFORMATION

FDA Wants More Data on Saxagliptin Dapagliflozin Combo Diabetes Medication

Were you looking for Saxagliptin - Onglyza and Kombiglyze XR Side Effects lawsuits?


Washington, DC: A new diabetes medication that combines two existing AstraZeneca drugs, Saxagliptin and dapagliflozin, has been denied approval by the Food and Drug Administration. The agency has asked AZ for more data which may warrant new clinical trials.

Had the combination treatment been approved, it would have been competed directly with Glyxambi from Lilly.

According to a company statement, data from a late-stage clinical trial showed the AstraZeneca combination therapy helped reduce blood sugar levels more than either drug taken alone. In both cases the treatments were combined with metformin, an inexpensive generic drug typically given as the first step in treating diabetes.

Saxagliptin, marketed under the brand name Onglyza, is part of a class of drugs called DPP-4 inhibitors. The treatments help the body make more insulin, which helps remove sugar from the blood. Dapagliflozin, sold as Farxiga, Xigduo XR in the US, is an SGLT-2 inhibitor, a type of drug that blocks sugar from being absorbed into the kidneys. Instead excess sugar is excreted through the urine, helping control diabetes.

In March 2014, the FDA requested clinical trial data from the AZ on saxagliptin to investigate a possible association between use of the type 2 diabetes drug and heart failure.

The request resulted from a study published in the New England Journal of Medicine (NEJM), which reported an increased rate of hospitalization for heart failure, when the heart does not pump blood well enough, with use of saxagliptin (marketed as Onglyza and Kombiglyze XR) compared to an inactive treatment. The study did not find increased rates of death or other major cardiovascular risks, including heart attack or stroke, in patients who received saxagliptin.

In September of this year, the FDA issued a statement noting it is continuing to evaluate the risk of bone fractures with drugs in the SGLT2 inhibitor class, including dapagliflozin and empaglifozin (Jardiance, Glyxambi, Synjardy), to determine if additional label changes or studies are needed.



Legal Help

If you or a loved one has suffered similar damages or injuries, please click the link below and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.
Last updated on


ADD YOUR COMMENT ON THIS ISSUE

Fields marked * are mandatory. Please read our comment guidelines before posting.

*Name:

Note: Your name will be published with your comment.

*Email Address:

Your email will only be used if a response is needed.
*Your Comment:

Are you the defendant or a subject matter expert on this topic with an opposing viewpoint? We'd love to hear your comments here as well, or if you'd like to contact us for an interview please submit your details here.
Request Legal Help Now! - Free